Download
00381_2024_Article_6463.pdf 1,49MB
WeightNameValue
1000 Titel
  • MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models
1000 Autor/in
  1. Sigaud, Romain |
  2. Brummer, Tilman |
  3. Kocher, Daniela |
  4. Milde, Till |
  5. Selt, Florian |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-05-25
1000 Erschienen in
1000 Quellenangabe
  • 40(10):3209-3221
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00381-024-06463-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511703/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Understanding the molecular and cellular mechanisms driving pediatric low-grade glioma (pLGG)—the most prevalent brain tumor in children—is essential for the identification and evaluation of novel effective treatments. This review explores the intricate relationship between the mitogen-activated protein kinase (MAPK) pathway, oncogene-induced senescence (OIS), the senescence-associated secretory phenotype (SASP), and the tumor microenvironment (TME), integrating these elements into a unified framework termed the MAPK/OIS/SASP/TME (MOST) axis. This integrated approach seeks to deepen our understanding of pLGG and improve therapeutic interventions by examining the MOST axis’ critical influence on tumor biology and response to treatment. In this review, we assess the axis’ capacity to integrate various biological processes, highlighting new targets for pLGG treatment, and the need for characterized in vitro and in vivo preclinical models recapitulating pLGG’s complexity to test targets. The review underscores the need for a comprehensive strategy in pLGG research, positioning the MOST axis as a pivotal approach in understanding pLGG. This comprehensive framework will open promising avenues for patient care and guide future research towards inventive treatment options.</jats:p>
1000 Sacherschließung
lokal Cellular Senescence/physiology [MeSH]
lokal Humans [MeSH]
lokal MAPK pathway
lokal Animals [MeSH]
lokal Pediatric low-grade glioma
lokal Microenvironment
lokal Senescence-associated secretory phenotype
lokal Glioma/pathology [MeSH]
lokal Tumor Microenvironment/physiology [MeSH]
lokal MAP Kinase Signaling System/physiology [MeSH]
lokal Review
lokal Oncogene-induced senescence
lokal Child [MeSH]
lokal Brain Neoplasms/pathology [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2lnYXVkLCBSb21haW4=|https://frl.publisso.de/adhoc/uri/QnJ1bW1lciwgVGlsbWFu|https://frl.publisso.de/adhoc/uri/S29jaGVyLCBEYW5pZWxh|https://frl.publisso.de/adhoc/uri/TWlsZGUsIFRpbGw=|https://frl.publisso.de/adhoc/uri/U2VsdCwgRmxvcmlhbg==
1000 Hinweis
  • DeepGreen-ID: 0854b0420b8d4bf086f54daa6f9a5f97 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsche Forschungsgemeinschaft |
  2. The Everest Centre for Low-grade Paediatric Brain Tumors |
  3. Biomed Valley Discoveries, Inc. |
  4. Day One Biopharmaceuticals |
  5. Deutsches Krebsforschungszentrum (DKFZ) |
1000 Fördernummer
  1. -
  2. -
  3. -
  4. -
  5. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
  5. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer The Everest Centre for Low-grade Paediatric Brain Tumors |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Biomed Valley Discoveries, Inc. |
    1000 Förderprogramm -
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer Day One Biopharmaceuticals |
    1000 Förderprogramm -
    1000 Fördernummer -
  5. 1000 joinedFunding-child
    1000 Förderer Deutsches Krebsforschungszentrum (DKFZ) |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6519891.rdf
1000 Erstellt am 2025-07-05T21:10:07.925+0200
1000 Erstellt von 322
1000 beschreibt frl:6519891
1000 Zuletzt bearbeitet 2025-08-11T08:04:48.895+0200
1000 Objekt bearb. Mon Aug 11 08:04:48 CEST 2025
1000 Vgl. frl:6519891
1000 Oai Id
  1. oai:frl.publisso.de:frl:6519891 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source